G Protein-Coupled Receptor 30 (GPR30) Expression Pattern in Inflammatory Bowel Disease Patients Suggests its Key Role in the Inflammatory Process. A Preliminary Study

Marcin Włodarczyk 1*, Aleksandra Sobolewska-Włodarczyk 1,2*, Adam I. Cygankiewicz 3, Damian Jacenik 3, Aleksandra Piechota-Połańczyk 2, Krystyna Stec-Michalska 2, Wanda M. Krajewska 3, Jakub Fichna 1, Maria Wiśniewska-Jarosińska 2

INTRODUCTION

Inflammatory bowel diseases (IBD) constitute a large group of chronic disorders of the gastrointestinal (GI) tract, which are characterized by chronic granulomatous inflammation with periods of exacerbations and remissions. The most common representatives within this group are Crohn's disease (CD) and ulcerative colitis (UC) [1]. The pathophysiology of the intestinal lesions in IBD is not entirely understood and many factors, including genetic, microbial, and environmental are believed to trigger the disease [2]. Recent studies suggest a strong impact of the immune system hyperactivation and elevated pro-inflammatory cytokine levels on the development of IBD [3]. Crohn's disease is associated with an exaggerated Th1 mediated response, characterized by enhanced production of interleukin (IL)-1, IL-2, IL-6, IL-12, IL-18, TNF-α and IFN-γ. On the other hand, in UC there is an enhanced production of Th2 cytokines, IL-4, IL-5, and IL-10. However, this classic view of Th1/Th2 mutually exclusive has recently been challenged, as an increased number of IL-17 producing cells (Th17) has been found in samples from patients with both CD and UC [4].

The major IBD symptoms include abdominal pain, diarrhea, blood in the feces, weight loss and fatigue. The idiopathic
inflammatory intestinal process related to IBD is strongly associated with a decreased patient's quality of life and requires advanced clinical intervention. However, a significant rate of loss of response or even the lack of any therapeutic effect is often observed with currently available anti-IBD treatments. Therefore, novel potential drug targets are now being investigated [1-3].

The design of novel therapeutics is impaired by our incomplete understanding of the pathophysiology of IBD and consequently poor insight into the changes in the immune system during IBD development. Several newly described receptors and pathways that may be involved in pathological immunological response in IBD are currently regarded as being the potential target for future anti-IBD drugs. These include recently de-orphanized receptors, i.e. proteins that have a structure similar to that of other identified receptors, but for which the first endogenous ligand has been recently identified [5]. Of all new de-orphanized receptors, the G protein - coupled receptor 30 (GPR30), also known as the G protein - coupled estrogen receptor 1 (GPER) is of particular interest [6].

Female sex hormones, estrogens, are known to exert anti-atherogenic and anti-inflammatory effects [7]. Estrogen (ER) effects are mediated by activation of three different receptors: classical estrogen receptors ERα and ERβ, and GPR30 [8-11]. It has been shown that the activation of GPR30 blocks the immunological pathways dependent on pro-inflammatory proteins, such as tumor necrosis factor-α (TNF-α), intracellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) [7]. However, very little is known about the GPR30 protein expression in the GI tract and its role in the development of IBD.

The aim of this pilot study was to determine whether GPR30 is expressed in the colonic tissue of IBD patients and if so, whether the GPR30 expression differs between non-IBD and IBD patients.

**METHODS**

**Study group**

Fifty-seven patients divided into three groups were enrolled in the study: controls (n=15), CD (n=20) and UC (n=22) patients. The patients were matched by age; additionally, the IBD patients were matched by sex. The control group included healthy subjects that were diagnosed as IBD-free by colonoscopy and the results confirmed by histopathological examination. None of the female subjects enrolled in the study were in the menopausal phase. In each participating subject colonoscopy after signing an informed consent, two endoscopic biopsy specimens were prelevated from different colonic inflamed and non-inflamed areas (IBD patients: CD and UC), and in controls from different non-inflamed colonic areas. In all IBD patients the endoscopic biopsies from macroscopic inflamed and non-inflamed areas were drawn. The colonic samples were stored at -80°C for further biochemical analysis. Based on additional biopsy specimens stored in 10% formalin the inflammatory involvement of the tissue was confirmed in histopathological routine H&E staining. Tissue was considered non-inflamed if there was an absence of macroscopic or histological evidence of inflammation.

**RNA isolation**

Total RNA extraction was performed using Tri Reagent (Sigma Aldrich, Germany) and PureLink RNA Mini Kit (Life Technologies, USA). Briefly, the tissue was minced and homogenized in Tri Reagent, after centrifugation and separation of the phases, the upper, aqueous phase was mixed 1:1 (v/v) with the lysis buffer and loaded onto the column, subsequent steps were conducted according to manufacturer's protocol.

The quality and quantity of total RNA was estimated spectrophotometrically with BioPhotometer plus (Eppendorf, Germany). The sample was characterized with A260 nm/A280 nm ratio, which was in the range of 1.79-2.01.

**Reverse transcription**

cDNA synthesis was performed with the ReverTaid First Strand cDNA Synthesis Kit (Fermentas, Canada) in accordance with the manufacturer’s protocol. Total RNA (1 µg) was used in reverse transcription reaction in a total volume of 20 µl with the following three step incubation: 25°C for 5 min, 42°C for 60 min and 70°C for 5 min.

**Quantitative real-time RT-PCR**

For the quantification of mRNA expression, we applied the real-time fluorescence detection PCR method with FAM dye-labeled TaqMan probes (Applied Biosystems, USA). Values obtained for studied genes were normalized to the expression of GAPDH (glyceraldehyde 3-phosphate dehydrogenase) gene as an endogenous control. The catalog numbers for the probes used are as follows: GPR30 – Hs01922715_s1, GAPDH – Hs99999905_m1. The real-time reaction mixture was prepared in a total volume of 10 µl and consisted of 0.5 µl cDNA, 5 µl TaqMan Gene Expression Master Mix, 0.5 µl TaqMan Gene Expression Assays and 4 µl RNA-free water and was performed as triplicate. The cDNA was amplified in Mastercycler Realplex (Eppendorf, Germany). Cycle parameters were as follows: initial denaturation at 95°C for 10 min, followed by 40 cycles of sequential incubations at 95°C for 15 s and at 60°C for 1 min.

The fluorescent dye emission was a function of the cycle number. The initial amount of the template was evaluated as a Ct parameter. Ct value was the threshold cycle number at which PCR amplification reached a significant threshold. The number of the cycle was linearly correlated with logarithmic value of RNA quantity. The relative expression level normalized to GAPDH was calculated as 2^[−(ΔΔCt)GPR30–CtGAPDH] x1000.

J Gastrointestin Liver Dis, March 2017 Vol. 26 No 1: 29-35
Protein extraction and quantification
Tissue scraps were homogenized following a protocol provided with tissue lysis buffer for the whole cell lysate (Sigma-Aldrich). Briefly, around 10 mg of tissue was added to 1 ml of tissue lysis buffer (Sigma-Aldrich) and homogenized on ice for 30 seconds with tissue raptor (IKE, Germany). Next, the samples were centrifuged 10,000xg, 10 min, 4°C and protein level was assayed using modified Lowry’s method.

GPR30 detection by Western blot
The GPR30 and GAPDH proteins content in biopsy specimens were detected using the immunoenzymatic (Western blot) method with specific primary antibodies against GPR30 and GAPDH proteins. Equal protein amounts of tissue extracts were separated by SDS-PAGE. After electrophoresis, proteins were transferred on nitrocellulose and incubated overnight at 4°C with consecutive primary rabbit anti-human monoclonal antibodies at concentrations 1:1,000 in PBS for GPR30, and 1:3,000 in PBS for GAPDH (Santa Cruz, Cell Signaling, UK and USA, respectively). Next, the secondary HRP-conjugated donkey antibodies were used at concentrations 1:5,000 in PBS+Tween 20 (0.05%) for GPR30 and 1:1,000 in PBS for GAPDH (Santa-Cruz). The pico- or femtoluminol reagents (Thermo Scientific) and X-ray films (Thermo-Scientific) were used to visualize the reaction. Finally, signal intensity was quantified using ImageJ software (Canada) and normalized to GAPDH.

Each assay was performed in triplicates with tissue samples from different donors.

Statistical analysis
Continuous demographic and biochemical data are presented as means ± SEM, while demographic categorical data were described with absolute frequencies and percentages. Statistical analysis was performed using Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA). An analysis of variance (one-way ANOVA) followed by Newman-Keuls post hoc testing and Bonferroni correction post-test were used to calculate differences. P values <0.05 were considered statistically significant. Ct values obtained for reference gene were tested using Grubbs test for possible outliers.

Ethics statement
The study was conducted in accordance with the ethical principles of the 1975 Declaration of Helsinki and the Committee of Bioethics of Medical University of Lodz approved the study protocol (RNN/515/13/KB). All participating subjects gave written, informed consent prior to enrollment.

RESULTS

Patients’ characteristics
Fifty-seven patients who were hospitalized at the Department of Gastroenterology at the Medical University of Lodz, Poland were enrolled in our study: 28 women and 29 men. Detailed demographic characteristics, laboratory findings and treatment history are presented in Table I. The analyzed groups (Control, CD, and UC) were homogeneous in terms of age and gender of the patients. The percentage of smokers in the CD and UC groups was similar (20% and 27%, respectively; p=0.581).

The white blood cell (WBC) levels in all analyzed groups were comparable (p=0.891) and no gender-related significant difference in WBC concentration was observed (p=0.795). The CD and UC patients had a weak tendency to elevated blood C-reactive protein (CRP) levels compared to the control group (p=0.061 and p=0.172, respectively).

| Table I. Detailed demographic characteristics and laboratory findings in the patients with inflammatory bowel diseases and controls enrolled into the study. |
| Subjects, n (%) | Crohn’s disease | Ulcerative colitis | Control group | p-value |
| Subjects, n (%) | 20 | 22 | 15 | NA |
| Gender, n (%) | | | | |
| women | 10 (50%) | 11 (50%) | 7 (46%) | 0.976 |
| men | 10 (50%) | 11 (50%) | 8 (53%) | |
| Age, years | 24.3±3.6 | 26.7±4.4 | 25.7±4.4 | 0.562 |
| BMI, kg/m² | 21.1±2.4 | 21.0±1.7 | 21.6±1.3 | 0.653 |
| 5-ASA/SASP | 11 (55%) | NA | 15 (68%) | 0.379 |
| Corticosteroid history, n (%) | | | | |
| Never used | 2 (10%) | 3 (14%) | 13 (87%) | NA |
| ≤1 year | 4 (20%) | 3 (14%) | 2 (13%) | |
| >1 year to ≤2 years | 4 (20%) | 10 (46%) | 6 (26%) | 0 (0%) |
| >2 years | 10 (50%) | 6 (26%) | 6 (26%) | 0 (0%) |
| Hematocrit, % | 39.4±9.4 | 38.4±9.9 | 43.6±11.4 | 0.325 |
| White blood cell count, x 10³/μl | 7.37±2.70 | 6.97±2.61 | 7.11±2.59 | 0.891 |
| Platelet count, x 10³/μl | 329±149 | 289±89 | 246±47 | 0.245 |
| Mean platelet volume, fl. | 11.25±0.99 | 10.89±0.91 | 11.29±1.08 | 0.783 |
| CRP, mg/l | 4.6±5.9 | 3.8±5.1 | 0.7±0.8 | 0.054 |

Data are presented as mean±standard deviation or number (percentage).
BMI: body mass index; 5-ASA: 5-aminosalicylate; SASP: sulfasalazine; CRP: C-reactive protein; NA: not applicable
GPR30 mRNA expression in the colonic tissue

GPR30 mRNA was detected in all samples tested. The level of expression of GPR30 mRNA was comparable in non-inflamed colonic tissues in all analyzed groups (p=0.572). Moreover, there were no differences in GPR30 mRNA expression in inflamed colonic tissues in the CD vs. UC patients (p=0.244). In addition, similar GPR30 mRNA expression levels in inflamed compared with non-inflamed colonic tissue were observed in the CD group (p=0.319) and in the UC group (p=0.244) (Fig. 1). Finally, no significant differences of GPR30 mRNA expression in CD and UC patients were observed when patients were divided by sex (CD: p=0.854; UC: p=0.675).

GPR30 protein expression in the colonic tissue

The GPR30 protein expression was detected in all tested colonic tissues. In non-inflamed colonic tissues, there was a significant difference in GPR30 protein expression among all analyzed groups (p=0.0496) (Fig. 2). Namely, the level of GPR30 protein was significantly increased in CD patients (1.501±0.270 vs. 0.273±0.070, p=0.014), but only moderately and not significantly in UC patients (1.152±0.335 vs. 0.273±0.070; p=0.143), as compared with controls.

We further analyzed the GPR30 protein levels in the inflamed vs. non-inflamed colonic tissues. There were no significant differences in GPR30 protein expression between CD and UC either in non-inflamed (1.501±0.270 vs. 1.152±0.335; p=0.432) (Fig. 2) or inflamed colonic tissues (0.845±0.231 vs. 1.134±0.337; p=0.491) (Fig. 3). In the CD patients, a significantly lower GPR30 protein content in the inflamed than in non-inflamed tissue was observed (0.690±0.186 vs. 1.437±0.285; p=0.039) (Fig. 4). In the UC patients, no difference in colonic GPR30 protein level in the inflamed and non-inflamed tissues was observed (1.134±0.337 vs. 1.071±0.411; p=0.909) (Fig. 5). When patients were divided by sex, there were no differences in the colonic GPR30 protein expression between female and male inflamed, as well as between female and male non-inflamed tissues (Fig. 6). However, a significantly lower level of GPR30 in inflamed compared to non-inflamed tissues in female CD patients was observed; a similar trend was observed for male CD patients (men: 0.854±0.381 vs. 1.766±0.463; p=0.032; women: 0.834±0.272 vs. 1.192±0.210; p=0.041).

DISCUSSION

In this study we provide evidence that GPR30 is expressed in colonic tissue specimens and may be involved in the intestinal inflammatory balance. Importantly, we observed higher GPR30 protein levels in IBD patients than in healthy controls, which may underline its role in the development of colonic inflammatory lesions. Of note, we also found differences in GPR30 protein expression between non-inflamed and inflamed areas of colonic tissue of CD, but not UC patients.

The G-protein coupled receptor GPR30 was identified in 1997, but its role was established only in 2005 [8, 12]. It was shown that GPR30 is involved, among others, in the
activation of actin polymerization and the inhibition of cellular proliferation in human umbilical vein endothelial cells [13]; others found that the GPR30 agonist inhibits cardiac cell growth [14]. Recent studies implicate the role of GPR30 in aggressive forms of breast, ovarian and endometrial cancers [15]. GPR30 has also become an interesting target for studies on the GI tract. Qin et al. showed differential distribution of GPR30, ERα and ERβ in human colonic mucosa [16]. It was also observed that the expression of GPR30 in the cytoplasm of mast cells and GPR30-positive cells was significantly higher in diarrhea-predominant IBS (D-IBS) patients than in constipation-predominant IBS (C-IBS) patients and healthy subjects [16]. Noteworthy, ERα and ERβ were largely absent in mast cells in colonic mucosa and no difference in immunostaining for ERα and ERβ was found among these three groups.

Our study suggests that GPR30 may play a crucial role in intestinal inflammation and could be considered as a potential target for anti-inflammatory treatment. This is in line with other recent studies, in which the activation of GPR30 produced anti-inflammatory effects. For example, Blasko et al. and Weil et al. demonstrated the anti-inflammatory effect on GPR30 activation in rodent models of multiple sclerosis and ischemia-reperfusion injury [17-18]. Similarly, Chakrabarti et al. detected GPR30 protein expression in cultured human endothelial cells, interestingly with a predominant localization in the cell nuclei, and observed that the activation of the endothelial GPR30 attenuated the TNFα-induced up-regulation of proinflammatory leukocyte adhesion molecules [7]. Of note, previously published data also indicated a possible implication of GPR30 in the inflammatory processes in the GI tract. Luo et al. found that the GPR30 expression in human

Fig. 4. Significant difference in GPR30 protein expression in CD patients in non-inflamed vs. inflamed colonic tissues. Data presented as means ± SEM (top panel); representative blot (bottom panel).

Fig. 5. No difference in GPR30 protein expression in UC patients in non-inflamed and inflamed colonic tissues. Data presented as means ± SEM (top panel); representative blot (bottom panel).

Fig. 6. GPR30 protein expression sex related differences in the non-inflamed and inflamed colonic in CD (A, B) and UC (C, D) patients.
Changes of GPR30 expression exclusively on protein but not at mRNA level may suggest that reduced protein turnover and increased protein stability in CD patients take place. The lack of compatibility between alteration of protein and mRNA expression confirms that there is no simple and direct relation between transcriptome and proteome, and GPR30-mediated regulation in inflammatory bowel diseases involves various mechanisms.

CONCLUSION

GPR30 is detectable in the colonic tissue of IBD patients. Importantly, higher protein levels of GPR30 characterize the non-inflamed areas of colonic tissue in CD, but not in UC patients. Furthermore, the up-regulation of GPR30 in non-inflamed areas of CD patients seems to be gender-independent. Our observations indicate that GPR30 may play a role in the inflammatory process in IBD patients, thus affecting disease severity, as well as the response to treatment. Depending on the outcomes of further investigation, GPR30 receptors may become an attractive target for novel drugs in the treatment of IBD, particularly in CD patients.

Conflicts of interest: Nothing to disclose.


Acknowledgement: This research was supported by the grants from the Medical University of Lodz (#503/1-156-04/503-01 to JF) and the National Science Center (2015/17/N/NZ5/00336 to DJ).

REFERENCES